An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer

Published:2019-08-24 Issue:12 Volume:24 Page:1596-1604
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Tsuchiya Tomohiro,Imanaka Keiichiro,Iwaki Yuki,Oyama Ryo,Hashine Katsuyoshi,Yamaguchi Akito,Uemura Hiroji^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-019-01526-7.pdf

Reference16 articles.

1. Bray F, Jerlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortaility worldwide for 36 caancers in 185 countries. CA Cancer J Clin 68(6):394–424

2. Foundation for promotion of cancer research (2014) Cancer statistics in Japan—2014. Available via DIALOG. https://ganjoho.jp/data/reg_stat/statistics/brochure/2014/cancer_statistics_2014_fig_E.pdf . Accessed Nov 2018

3. Hori M, Matsuda T, Shibata A et al (2015) Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 45(9):884–891

4. Matsubara N, Mukai H, Hosono A et al (2017) Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol 80(6):1063–1072

5. Chong JT, Oh WK, Liaw BC (2018) Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date. OncoTargets Ther 11:2141–2147

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes in studies regarding older patients with prostate cancer: A systematic review;Journal of Geriatric Oncology;2024-06

2. Apalutamide-Induced Toxic Epidermal Necrolysis in a Caucasian Patient with Metastatic Castration-Sensitive Prostate Cancer: A Case Report and Review of the Literature;Case Reports in Oncology;2023-08-16

3. A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system;Frontiers in Pharmacology;2023-06-05

4. Acute generalized exanthematous pustulosis during apalutamide treatment in a patient with prostate cancer;IJU Case Reports;2022-08-16

5. Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium;International Journal of Clinical Oncology;2022-05-20